Collectively, current evidence supports naringenin's multi-target protective actions against AD-related cognitive impairment via the modulation of amyloid/tau pathology, PI3K/AKT/GSK-3β and insulin pathways, cholinergic neurotransmission, the CRMP2 axis, and enzyme inhibition, as well as through antioxidative and anti-inflammatory mechanisms. This evidence concerns the gene MAPT and Alzheimer disease.